Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5484-5492

  Garcia Carbonero, R ^a   Supko, J G ^a   Maki, R G ^a   Manola, J ^a   Ryan, D P ^a   Harmon, D ^a   Puchalski, T A ^a   Goss, G ^a   Seiden, M V ^a   Waxman, A ^a   Quigley, M T ^a   Lopez, T ^a   Sancho, M A ^a   Jimeno, J ^a   Guzman, C ^a   Demetri, George D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ONDANSETRON; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER FATIGUE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FIBROSARCOMA; HUMAN; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LIVER INJURY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TRANSAMINITIS; VOMITING; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 24944460785     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.028     Document Type: Article

References (42)

1. Demetri GD: Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr Opin Oncol 10:343-347, 1998
2. Fisher C: Current aspects of the pathology of soft tissue sarcomas. Semin Radiat Oncol 9:315-327, 1999
3. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
4. Bramwell VHC, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311-322, 1986
5. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
6. Antman K, Crowley J, Balcerzak S, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
7. Rinehart KL, Holt TG, Fregeau NL, et al: Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 55:4512-4515, 1990
8. Jimeno JM, Faircloth G, Cameron L, et al: Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs Future 21: 1155-1165, 1996
9. Pommier Y, Kohlhagen G, Bailly C, et al: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309, 1996
10. Moore BM, Seaman FC, Hurley LH: NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 119:5475-5476, 1997
11. Minuzzo M, Marchini S, Broggini M, et al: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97:6780-6784, 2000
12. D'Incalci M, Erba E, Faretta M, et al: New drugs of marine origin. Ann Oncol 7:S34, 1996 (suppl 1)
13. Jin S, Gorfajn B, Faircloth G, et al: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97:6775-6779, 2000
14. Takebayashi Y, Pourquier P, Zirnonjic DB, et al: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961-966, 2001
15. Hendriks HR, Fiebig HH, Giavazzi R, et al: High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10:1233-1240, 1999
16. Li WW, Takahashi N, Jhanwar S, et al: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7:2908-2911, 2001
17. Van Kesteren C, Twelves C, Bowman A, et al: Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13:381-393, 2002
18. Taamma A, Misset JL, Riofrio M, et al: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256-1265, 2001
19. Villalona-Calero MA, Eckhardt SG, Weiss G, et al: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 8:75-85, 2002
20. Ryan DP, Supko JG, Eder JP Jr, et al: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7:231-242, 2001
21. Cvetkovic RS, Figgitt DP, Plosker GL: Ecteinascidin-743 (ET-743). Drugs 62:1185-1192, 2002 [Erratum: Drugs 62:1634, 2002]
22. van Kesteren C, Cvitkovic E, Taamma A, et al: Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6:4725-4732, 2000
23. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al: Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309-319, 2002
24. National Cancer institute: Common toxicity criteria, version 2.0. http://ctep.cancer.gov/ reporting/ctc.html.
25. World Health Organization: WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
26. Mizuta E, Tsubotani A: Preparation of mean drug concentration-time curves in plasma: A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 33:1620-1632, 1985
27. Lacey LF, Keene ON, Pritchard JF, et al: Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed? J Biopharm Stat 7:171-178, 1997
28. Lam FC, Hung CT, Perrier DG: Estimation of variance for harmonic mean half-lives. J Pharm Sci 74:229-231, 1985
29. Simon R: Optimal two-stage designs for clinical trials. Control Clin Trials 10:1-10, 1989
30. Atkinson EN, Brown BW: Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 41:741-744, 1985
31. Judson I, Radford JA, Harris M, et al: Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877, 2001
32. van Oosterom AT, Mouridsen HT, Nielsen OS, et al: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406, 2002
33. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676-2684, 2000
34. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
35. Garcia-Carbonerro R, Supko J, Manola J, et al: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues after failure of conventional chemotherapy. J Clin Oncol 22:1480-1490, 2004
36. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150-157, 1999
37. Gómez J, López Lázaro L, Guzmán C, et al: Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol 19:187a, 2000 (abstr 727)
38. Le Cesne A, Blay JY, Judson I, et al: ET-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC Phase II Trial. Proc Am Soc Clin Oncol 20:353a, 2001 (abstr 1407)
39. Delaloge S, Yovine A, Taamma A, et al: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 19: 1248-1255, 2001
40. Laverdiere C, Kolb EA, Supko JG, et al: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832-840, 2003
41. Takashashi N, Li W, Banerjee D, et al: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251-3257, 2001
42. Meco D, Colombo T, Ubezio P, et al: Effective combination of ET-743 and doxorubicin in sarcoma: Preclinical studies. Cancer Chemother Pharmacol 52:131-138, 2003